#United States #San Diego #Blacksmith Medicines #oncology research #FEN1

Blacksmith Medicines to Present at AACR Annual Meeting 2026

On April 16, 2026, Blacksmith Medicines, Inc., a frontrunner in biopharmaceuticals, announced that it will be presenting significant findings from its oncology program. This presentation will focus on flap endonuclease 1 (FEN1), a metallonuclease involved in DNA repair and replication processes. The presentation is slated for the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place at the San Diego Convention Center from April 17 to April 22, 2026.

The Significance of FEN1 in Cancer Therapeutics

FEN1 plays a crucial role in repairing DNA flaps created during replication and repair mechanisms. This places it at the forefront of cancer treatment research, as it is frequently overexpressed in various tumors. Moreover, FEN1 has a multitude of synthetic lethality interactions with genes in the homologous recombination (HR) pathway, making it a valuable target for therapeutic development.

Presentation Details

The details of the presentation are as follows:

• - Abstract Number: 234
• - Title: "Proteomic profiling of FEN1 inhibition by BSM-1516 reveals chromatin-associated biomarkers for preclinical pharmacodynamic evaluation"
• - Session Title: DNA Damage and Repair 1
• - Session Date and Time: Sunday, April 19, 2026, from 2:00 PM to 5:00 PM
• - Location: Poster Section 11, Poster Board Number 5

The abstract can be viewed on the AACR Annual Meeting 2026 website.

About Blacksmith Medicines' Platform

The platform developed by Blacksmith is pioneering the approach to metalloenzymes, a critical class of enzymes that utilize metal ion cofactors for their biological functions. Historically, targeting these enzymes has posed significant challenges to researchers due to complexities in small-molecule chemistry. Blacksmith addresses these hurdles with a proprietary library of metal-binding pharmacophores, a comprehensive database mapping metalloenzyme functions and disease correlations, and specialized tools for structure-based drug design.

Strategic Collaborations

In their quest to innovate therapeutic solutions, Blacksmith Medicines has partnered with several industry leaders, including Basilea Pharmaceutica International Ltd. and Eli Lilly and Company. The company has also secured non-dilutive funding from notable organizations such as CARB-X and NIH/NIAID, highlighting its commitment to advancing therapeutic strategies against cancer.

Financial Backing and Support

Blacksmith Medicines has attracted investments from several prominent firms, including Lilly and Evotec A.G. This strong financial backing supports the company's growth and allows it to explore new advancements in metalloenzyme targeting therapeutics, with the aim of bringing forth viable cancer treatment options.

For further updates and insights, visit Blacksmith Medicines' official website or follow the company on LinkedIn for the latest developments in research and therapeutics focusing on metalloenzymes.

Contact for media inquiries:

• - Amy Conrad
• - Juniper Point
• - email
• - Phone: 858-366-3243

As Blacksmith Medicines prepares for this vital presentation, the scientific community will undoubtedly be eager to learn more about the innovative approaches being taken in the fight against cancer through the novel targeting of metalloenzymes.